Testing different PANZYGA doses for children with CIDP
Part of Brain & nervous system, Immune system & allergy clinical trials.
This Phase 3 study compares different dose schedules of PANZYGA (immune-globulin) in children with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). It aims to find a dosing plan that is both safe and effective for improving symptoms and function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 2 and 17 years old
- Have a confirmed CIDP diagnosis, and symptoms that limit daily function
- Your doctor rates your disability as mRS 2 to 5 (moderate to more severe, not fully disabling)
- Parent/guardian can sign consent, and the child can give assent if age-appropriate
- If you recently used immune treatments, there must be an adequate washout period (or you must relapse during washout)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DNTH103 for adults with CIDP, a condition that affects nerves and causes weakness. It aims to see if the drug can help people who are currently on treatment, have tried treatment before, or are new to treatment.
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
This trial tests if a medication called Panzyga can help prevent infections in people with autoimmune conditions who have low antibody levels after B-cell therapy. It may be an option if you have a condition like multiple sclerosis, rheumatoid arthritis, or lupus.
This study tests whether two different dose levels of Privigen (a type of immune blood treatment) are safe and effective for children and teens with CIDP. It may help improve nerve-related symptoms in people whose CIDP has been confirmed or is being evaluated as likely.
This study tests if TAK-881 is as safe and effective as HYQVIA for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). You may join if you have been stable on immune globulin therapy and have certain disability levels.
Hear when a new Pediatric Chronic Inflammatory Demyelinating Polyneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.